Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?

Bibliography

• Gleevec (imatinib) package insert. Novartis Pharmaceuticals Corp; East Hanover, NJ: 2014
   Google Scholar
• Sprycel (dasatinib) package insert. Bristol-Myers Squibb Co; Princeton, NJ: 2014
   Google Scholar
• Tasigna (nilotinib) package insert. Novartis Pharmaceuticals Corp; East Hanover, NJ: 2014
   Google Scholar
• O’Brien SG, Guilot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O’Brien SG, Guilot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61
   PubMed Web of Science ®Google Scholar
• Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. ASH Annual Meeting Abstracts 2009;114:1126
   Google Scholar
• Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754-9
   PubMed Web of Science ®Google Scholar
• Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424-30
   PubMed Web of Science ®Google Scholar
• Baccarani M, Druker BJ, Branford S, et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol 2014;99:616-24
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-42
   PubMed Web of Science ®Google Scholar
• Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009;113:4497-504
   PubMed Web of Science ®Google Scholar
• Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006;354:2594-6
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and –intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12
   PubMed Web of Science ®Google Scholar
• Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014;123:2317-24
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123(4):494-500
   PubMed Web of Science ®Google Scholar
• Cortes J, Saglio G, Baccarani M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood (ASH Annual Meeting Abstracts) 2014;124:152
   Google Scholar
• O’Brien SG, Hedgley C, Adams S, et al. Spirit 2: an NCRI randomized study comparing dasatinib with imatinib in patients with newly diagnosed CML. Blood (ASH Annual Meeting Abstracts) 2014;124:517
   Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94:1765-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gatterman N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow up. Leukemia 2012;26:2197-203
   PubMed Web of Science ®Google Scholar
• Larson RA, Kim DW, Jootar S, et al. ENESTnd 5-year (y) update: long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). J Clin Oncol (Meeting Abstracts) 2014;32:7073
   Google Scholar
• Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusions in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14
   PubMed Web of Science ®Google Scholar
• Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimized the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-86
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Han X, Kantarjian H, et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-3
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Herndlhofer S, Schernthaner G, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-9
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012;12:337-40
   PubMed Web of Science ®Google Scholar
• Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011;86:610-11
   PubMed Web of Science ®Google Scholar
• Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27:1310-15
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63:789-99
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-8
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064-72
   PubMed Web of Science ®Google Scholar
• White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761-7
   PubMed Web of Science ®Google Scholar
• White DL, Radich J, Soverini S, et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses, and lower failure rates, than those randomized to standard-dose. Haematologica 2012;97:907-14
   PubMedGoogle Scholar
• Yeung DT, Vidovic L, Tang C, et al. KIR2DL5B genotype independently predicts poor outcomes in CML-CP patients switched to nilotinib after suboptimal responses to imatinib and may refine prognosis in patients with EMR failure. Blood (ASH Annual Meeting Abstracts) 2014;124:814
   Web of Science ®Google Scholar
• Marin D, Gabriel IH, Ahmad S, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2012;26:296-302
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122(6):872-84
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, O’Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 2011;29:4260-5
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, O’Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011;118:4541-6
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515-22
   PubMed Web of Science ®Google Scholar
• Mahon F, Richter J, Guilhot JG, et al. Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: The EURO-SKI study. Blood (ASH Annual Meeting Abstracts) 2014;124:151
   PubMed Web of Science ®Google Scholar
• Rea D, Nicolini FE, Tulliez M, et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months – on behalf of the French CML group filmc. Blood (ASH Annual Meeting Abstracts) 2014;124:811
   Web of Science ®Google Scholar
• Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance state: the cost of cancer care. J Clin Oncol 2009;27(23):3868-74
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011;364:2060-5
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum pretium-the just price. J Clin Oncol 2013;31:3600-4
   PubMed Web of Science ®Google Scholar
• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42
   PubMed Web of Science ®Google Scholar
• Larson RA, Conti R, Padula WV, et al. What is the most cost-effective strategy for treating newly diagnosed chronic myeloid leukemia (CML) after imatinib loses patent exclusivity? Blood (ASH Annual Meeting Abstracts) 2014;124:738
   Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F, et al. Adherence is the critical factor for achieving molecular respones in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
   PubMed Web of Science ®Google Scholar